RIKEN GENESIS became a Subsidiary of Sysmex -Reinforcing Our Structure Toward the Practical Realization of Genomic Medicine-

June 30, 2016


RIKEN GENESIS became a Subsidiary of Sysmex
-Reinforcing Our Structure Toward the Practical Realization of Genomic Medicine-

RIKEN GENESIS Co., Ltd. (HQ: Tokyo, Japan; President & CEO: Naoto Kondo) has been managed by two major shareholders, Toppan Printing Co., Ltd. (HQ: Tokyo, Japan; President & Representative Director: Shingo Kaneko) and Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu). Sysmex has acquired additional shares in RIKEN GENESIS from Toppan Printing, making RIKEN GENESIS a Sysmex subsidiary.
RIKEN GENESIS was reorganized with the appointment of Naoto Kondo as the new President & CEO, who has extensive experience with next-generation sequencers.

RIKEN GENESIS, provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience in the field of personalized medicine1. We provide highly reliable tests based on international quality standards, as demonstrated by its CLIA2 certification, being the first organization in Japan to meet this U.S. quality control standard for clinical laboratories.

Sysmex invested in RIKEN GENESIS in 2014, acquiring 36.5% of its shares, to advance the genetic testing business for personalized medicine. Since that time, the companies have been collaborating in operating the Sysmex Cancer Innovation Laboratory within the National Cancer Center, and advancing the development of clinical PCR3 and other efforts to realize personalized medicine.
With the aim of realizing genomic medicine4, for which there is a growing need as a component of personalized medicine, we plan to establish a new cutting-edge gene analysis center in Japan, centering on next-generation sequencers. We also plan to create a system that will allow for lab-assay services under CLIA standards collaborating with Sysmex.

RIKEN GENESIS and Sysmex will pursue R&D and business development initiatives to realize personalized medicine through genetic analysis.

Share Ownership Following the Acquisition
・Sysmex Corporation: 64.7%
・Toppan Printing Co., Ltd: 35.0%
・RIKEN Venture Capital Co., Ltd: 0.3%

Career History of the President & CEO of RIKEN GENESIS Co., Ltd.
Name: Naoto Kondo
Place of birth: Toki, Gifu Prefecture
Date of birth: March 16, 1956
Education: March 1983 Graduated from the Department of Agriculture, Nagoya University
Career History: April 1984 Entered Nippon Zoki Pharmaceutical Co., Ltd.
        Jan  1989 Entered JASCO Corporation
        March 1994 Entered Yokogawa Analytical Systems Inc. (Presently Agilent Technologies)
        Feb  2006 Entered Illumina KK (Illumina Japan)
        Jan  2007 General Manager of Illumina KK (Illumina Japan)
        Jan  2012 Entered RIKEN
        June 2016 Entered Sysmex Corporation (Assigned to RIKEN GENESIS)
              Appointed President and CEO of RIKEN GENESIS


1 Personalized medicine

A form of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease effectively.

2 U.S. Clinical Laboratory
Improvement Amendment(CLIA)

A CLIA-certified laboratory is required to undergo periodic inspections to ensure quality maintenance, ensuring the lab’s quality control in testing.

3 Clinical PCR

A fully-automated instrument that perform everything from DNA extraction to the analysis of gene abnormalities by simply setting a pathology specimen in place, simplifying genetic testing in a clinical environment.

4 Genomic medicine

Medicine which allows the prevention of disease, or the effective treatment of individual patients by analyzing their genetic information.

Press Release (PDF file)


Copyright © 2017 RIKEN GENESIS CO.,LTD. All Rights Reserved.